Importance of clinical worsening of heart failure treated in the outpatient setting: evidence from the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF)

Okumura, N. et al. (2016) Importance of clinical worsening of heart failure treated in the outpatient setting: evidence from the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). Circulation, 133(23), pp. 2254-2262. (doi: 10.1161/CIRCULATIONAHA.115.020729) (PMID:27143684)

[img]
Preview
Text
118328.pdf - Accepted Version

862kB

Abstract

Background—Many episodes of worsening of heart failure (HF) are treated by increasing oral therapy or intravenous treatment in the community or emergency department (ED), without hospital admission. We studied the frequency and prognostic importance of these episodes of worsening in PARADIGM-HF. Methods and Results—Outpatient intensification of HF therapy (IT) was added to an expanded composite outcome with ED visits, HF hospitalizations (HFh) and cardiovascular deaths. Examining first non-fatal events, 361/8399 patients (4.3%) had IT without a subsequent event (i.e. ED visit/HFh) within 30 days; 78/8399 (1.0%) had an ED visit without prior IT or a subsequent event within 30 days; and 1107/8399 (13.2%) had HFh without a preceding event. The risk of death (compared with "no event" patients) was similar after each manifestation of worsening - IT: HR=4.8(95%CI 3.9-5.9); ED visit: 4.5(3.0-6.7); HFh: 5.9(5.2-6.6). The expanded composite added 14% more events and shortened time to accrual of a fixed number of events. The benefit of sacubitril/valsartan over enalapril was similar to the primary outcome for the expanded composite (HR 0.79, 0.73-0.86) and was consistent across the components of the latter. Conclusions—Focusing only on HFh underestimates the frequency of worsening and the serious implications of all manifestations of worsening. For clinical trials conducted in an era of heightened efforts to avoid HFh, inclusion of episodes of outpatient treatment intensification (and ED visits) in a composite outcome adds an important number of events and shortens the time taken to accrue a target number of endpoints in an event-driven trial.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Jhund, Professor Pardeep and McMurray, Professor John
Authors: Okumura, N., Jhund, P. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Swedberg, K., Zile, M. R., Solomon, S. D., Packer, M., and McMurray, J. J. V.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:Circulation
Publisher:American Heart Association
ISSN:0009-7322
ISSN (Online):1524-4539
Published Online:20 April 2016
Copyright Holders:Copyright © 2016 American Heart Association, Inc.
First Published:First published in Circulation 133(23):2254-2262
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher

University Staff: Request a correction | Enlighten Editors: Update this record